Compare · MDGS vs RMD
MDGS vs RMD
Side-by-side comparison of Medigus Ltd. (MDGS) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDGS and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $27.91B, about 847.9x MDGS ($32.9M).
- RMD has hit the wire 7 times in the past 4 weeks while MDGS has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 0 for MDGS).
- Company
- Medigus Ltd.
- ResMed Inc.
- Price
- $2.48-1.98%
- $194.72+1.31%
- Market cap
- $32.9M
- $27.91B
- 1M return
- -
- -3.84%
- 1Y return
- -
- -22.70%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
Medigus Ltd.
Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools with direct visualization technology in the United States, the United Kingdom, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; develops and commercializes online and offline event planning software, as well as ticketing solutions; and operates online stores for the sale of various consumer products on the Amazon online marketplace. The company was incorporated in 1999 and is headquartered in Omer, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest MDGS
- Xylo Technologies: Viewbix Shares to Begin Trading on Nasdaq
- Xylo Technologies: Charging Robotics Successfully Installs Wireless EV Charging System in Automatic Parking Facility
- Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment
- Xylo Technologies: Revoltz Launches Commercial Phase of PORTO EV in Israel with First 50 Vehicles Delivered to Exclusive Distributor
- Xylo Technologies: Revoltz Receives Israeli Standards Institute Approval for PORTO EV Micro Vehicle
- Xylo Technologies: ParaZero Received Order from a Leading Tier-One Defense Company for 50 Drone Safety Systems
- Xylo Technologies: Revoltz to Launch an Innovative Three-Wheel Electric Cargo Bike for European and UK Markets
- Xylo Technologies Announces Plan to Implement ADS Ratio Change
- Xylo Technologies: Charging Robotics Lands Commercial Order for EV Wireless Charging Systems in Automatic Car Parks
- Xylo Technologies: Charging Robotics Secures First Commercial Order for EV Wireless Charging Systems in Automatic Car Parks
Latest RMD
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett